Table 1 Characteristics of cases and controls
From: Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case–control study
Cases ( n =1141) | Controls ( n =7954) | P value | |
|---|---|---|---|
Age at database enrolment (years, s.d.) | 57.3 (9.8) | 57.3 (9.8) | 1.0 |
Male sex (%) | 53.7 | 53.7 | 1.0 |
Mean duration of follow-up before index date (years, s.d.)) | 10.6 (3.4) | 10.6 (3.4) | 1.0 |
Smoking status | <0.005 | ||
Current smoker | 302 (26.5%) | 1372 (17.3%) | |
Non-smoker | 463 (40.6%) | 3961 (49.8%) | |
Ex-smoker | 235 (20.6%) | 1499 (18.9%) | |
Missing data | 141 (12.4%) | 1122 (14.1%) | |
Body mass index (kg m−2) | 0.1 | ||
<18.5 | 16 (1.4%) | 102 (1.3%) | |
⩾18.5 & <25 | 353 (31.0%) | 2323 (29.2%) | |
⩾25 & <30 | 343 (30.1%) | 2525 (31.8%) | |
⩾30 | 187 (16.4%) | 1108 (13.9%) | |
Missing | 242 (21.2%) | 1896 (23.8%) | |
Current drinking status | 0.4 | ||
Current drinker | 731 (64.1%) | 4992 (62.8%) | |
Non-drinker | 165 (14.5%) | 1107 (13.9%) | |
Ex-drinker | 7 (0.6%) | 77 (1.0%) | |
Missing data | 238 (20.9%) | 1778 (22.4%) | |
Hormone replacement therapy use | 0.3 | ||
Never | 1095 (95.9%) | 7574 (95.2%) | |
Ever | 46 (4.1%) | 380 (4.8%) | |
Steroid use | 0.2 | ||
Never | 990 (86.8%) | 6999 (88.0%) | |
Ever | 151 (13.2%) | 955 (12.0%) | |
Pancreatitis | <0.005 | ||
Never | 1085 (95.1%) | 7901 (99.3%) | |
Ever | 56 (4.9%) | 53 (0.7%) | |
Proton pump inhibitor use | 0.3 | ||
Never | 964 (84.5%) | 6817 (85.7%) | |
Ever | 177 (15.5%) | 1137 (14.3%) | |
H 2 antagonist use | <0.005 | ||
Never | 877 (76.9%) | 6423(80.8%) | |
Ever | 264 (23.1%) | 1531 (19.2%) | |
Diabetes | <0.005 | ||
Never | 1006 (88.2%) | 7442 (93.5%) | |
Ever | 135 (11.8%) | 512 (6.4%) | |
Prior cancer | 0.4 | ||
Never | 1049 (91.9%) | 7374 (92.7%) | |
Ever | 92 (8.1%) | 580 (7.3%) | |
Rheumatoid arthritis | |||
RA codes | 0.2 | ||
Never | 1131 | 8993 | |
Ever | 10 | 102 | |
Disease modifying anti-rheumatic drugs prescription | 0.9 | ||
Never | 1126 | 8993 | |
Ever | 15 | 102 | |
